Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that the ...

The primary efficacy outcome among the 550 participants with initially uncontrolled asthma showed significantly better ...

One of the few drug trials for a possible long Covid ended in disappointment. But lessons are leading to a second chance.

A new review urges oncology researchers to treat patient-reported outcomes as core trial endpoints — not just secondary stats ...

A national pilot study designed to determine if blood tests can help detect cancers earlier is open for enrollment.Results of ...

Viatris reported that its MR-139 ophthalmic ointment failed to meet its primary endpoint in a Phase III blepharitis trial, while advancing its MR-141 and MR-142 candidates in presbyopia and night ...

IRVINE, Calif., July 14, 2025 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the TrilogyTM Transcatheter Heart Valve (THV) System, today announced that patient ...

Suven Life Sciences today announced that the first patient has been randomized in its Phase-2b clinical trial evaluating ...

Hyderabad: Suven Life Sciences has announced that the first patient has been randomized in its Phase-2b clinical trial ...

A global study led by researchers at the School of Clinical Sciences at Monash Health, Monash University, has found that ...

In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or ...